DiaMedica Therapeutics Inc. filed a Form D with the Securities and Exchange Commission on 2025-07-25.
DiaMedica Therapeutics Inc. filed a Form D notice of an exempt securities offering with the SEC on July 25, 2025. The filing reports $30.10M sold. Its industry group is Biotechnology. It names Rick Pauls (Executive Officer, Director), Scott Kellen (Executive Officer), Lorianne Masuoka (Executive Officer) (SEC Form D, July 25, 2025).
Is this your company?
Sell to companies like DiaMedica Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-07-25 · the record
Pitching, partnering or investing alongside them? See who really runs and owns DiaMedica Therapeutics Inc.
Free to see. No signup.
More on the people and the money behind DiaMedica Therapeutics Inc., from the filings we hold.
Biotechnology raises by companies based in Minnesota, filed within 90 days of this one, largest first.
Get an email when DiaMedica Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when DiaMedica Therapeutics Inc. raises, hires or launches. No email unless you switch it on.
Watch DiaMedica Therapeutics Inc. →Get the full cited report on DiaMedica Therapeutics Inc.
What the filing shows about DiaMedica Therapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on DiaMedica Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives DiaMedica Therapeutics Inc.'s address as 301 Carlson Parkway, Suite 210, Minneapolis, MN 55305.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on DiaMedica Therapeutics Inc. See pricing
DiaMedica Therapeutics Inc. is a registered filer with the SEC (CIK 1401040) and has filed since 2023-04-18. 4 filings are on record, the latest on 2025-07-25.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
DiaMedica Therapeutics Inc.'s Form D of 2025-07-25 names Rick Pauls, Scott Kellen, Lorianne Masuoka and 7 more as its officers, directors or promoters.
Its new offerings report $80.19M sold across 4 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week.
Checked away from the filing. What is below does not come from the record on sec.gov.
DiaMedica Therapeutics is a biopharmaceutical company that specializes in creating synthetic proteins to treat a variety of conditions.
The title and description the site itself served, answering 200, after redirecting from https://diamedica.com. Not a cached copy and not the company's directory entry — what was live when we asked.
Rick Pauls is named as Executive Officer and Director on the Form D that DiaMedica Therapeutics Inc. filed with the SEC on 25 July 2025, one of 10 people that filing names.
Scott Kellen is named as Executive Officer on the Form D that DiaMedica Therapeutics Inc. filed with the SEC on 25 July 2025, one of 10 people that filing names.
Lorianne Masuoka is named as Executive Officer on the Form D that DiaMedica Therapeutics Inc. filed with the SEC on 25 July 2025, one of 10 people that filing names.
David Wambeke is named as Executive Officer on the Form D that DiaMedica Therapeutics Inc. filed with the SEC on 25 July 2025, one of 10 people that filing names.
Michael Giuffre is named as Director on the Form D that DiaMedica Therapeutics Inc. filed with the SEC on 25 July 2025, one of 10 people that filing names.
Richard Kuntz is named as Director on the Form D that DiaMedica Therapeutics Inc. filed with the SEC on 25 July 2025, one of 10 people that filing names.
Tanya Lewis is named as Director on the Form D that DiaMedica Therapeutics Inc. filed with the SEC on 25 July 2025, one of 10 people that filing names.
James Parsons is named as Director on the Form D that DiaMedica Therapeutics Inc. filed with the SEC on 25 July 2025, one of 10 people that filing names.
Daniel O'Connor is named as Director on the Form D that DiaMedica Therapeutics Inc. filed with the SEC on 25 July 2025, one of 10 people that filing names.
Charles Semba is named as Director on the Form D that DiaMedica Therapeutics Inc. filed with the SEC on 25 July 2025, one of 10 people that filing names.
10 people named on the filing — 4 holding an executive role and 6 as directors only.
Named as of the 2025-07-25 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about DiaMedica Therapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on DiaMedica Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on DiaMedica Therapeutics Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist DiaMedica Therapeutics Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind DiaMedica Therapeutics Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-11-01 (diamedica.com).
Each opens in a new tab, filled in for DiaMedica Therapeutics Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Minneapolis-St. Paul
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/diamedica-therapeutics-inc-form-d-25000001